miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 15, 2026

Is Newmont Stock Still a Buy After a 26% Rally in 3 Months? (Revised)

View original at nasdaq.com
Is Newmont Stock Still a Buy After a 26% Rally in 3 Months? (Revised) Newmont Corporation’s NEM shares have popped 26.2% in the past three months, buoyed by a surge in gold prices to record highs amid heightened geopolitical tensions and hopes of more interest rate cuts…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Earnings are expected to grow roughly 15.4% in 2026

    80% confidence

  • NEM expects fourth-quarter production of 1.415 million ounces, indicating a roughly 25% year-over-year decline

    80% confidence

  • For the fourth quarter, the company expects attributable production to be relatively in line with the third quarter

    80% confidence

  • Company anticipates generating $3 billion in after-tax cash proceeds from its 2025 divestiture program

    80% confidence

  • Retaining this Zacks Rank #3 (Hold) stock will be prudent for investors who already own it

    80% confidence

  • Ahafo North is expected to produce between 275,000 and 325,000 ounces of gold annually over an estimated mine life of 13 years

    80% confidence

  • Newmont anticipates maintaining its expected gold production for 2025 at about 5.9 million ounces

    80% confidence

  • Ahafo North production is expected to be 50,000 ounces this year, with a ramp-up to full capacity in 2026

    80% confidence

  • The Zacks Consensus Estimate for 2025 earnings is currently pegged at $6.32, suggesting year-over-year growth of 81.6%

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
Is Newmont Stock Still a Buy After a 26% Rally in 3 Months? (Revised) — Source | Via News | es.VIA.NEWS